189 related articles for article (PubMed ID: 35315067)
1. Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature.
Medrea I; Christie S; Tepper SJ; Thavorn K; Hutton B
Headache; 2022 Mar; 62(3):329-362. PubMed ID: 35315067
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster.
Medrea I; Christie S; Tepper SJ; Thavorn K; Hutton B
Headache; 2022 Apr; 62(4):482-511. PubMed ID: 35343597
[TBL] [Abstract][Full Text] [Related]
4. CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache.
Chen ST; Wu JW
Curr Pain Headache Rep; 2022 Sep; 26(9):667-675. PubMed ID: 35881279
[TBL] [Abstract][Full Text] [Related]
5. CGRP pathway monoclonal antibodies for cluster headache.
Chan C; Goadsby PJ
Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
[TBL] [Abstract][Full Text] [Related]
6. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
Khan S; Olesen A; Ashina M
Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
[TBL] [Abstract][Full Text] [Related]
7. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
8. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
9. Drug profile: galcanezumab for prevention of cluster headache.
Mudugal D; Monteith TS
Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
[No Abstract] [Full Text] [Related]
10. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
11. Galcanezumab for the prevention of cluster headache.
Giani L; Proietti Cecchini A; Leone M
Expert Opin Biol Ther; 2020 Oct; 20(10):1133-1142. PubMed ID: 32702245
[TBL] [Abstract][Full Text] [Related]
12. Anti-CGRP in cluster headache therapy.
Giani L; Proietti Cecchini A; Leone M
Neurol Sci; 2019 May; 40(Suppl 1):129-135. PubMed ID: 30820761
[TBL] [Abstract][Full Text] [Related]
13. Evolving options for the treatment of cluster headache.
Villar-Martinez MD; Chan C; Goadsby PJ
Curr Opin Neurol; 2020 Jun; 33(3):323-328. PubMed ID: 32209808
[TBL] [Abstract][Full Text] [Related]
14. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
[TBL] [Abstract][Full Text] [Related]
15. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial.
Vollesen ALH; Snoer A; Beske RP; Guo S; Hoffmann J; Jensen RH; Ashina M
JAMA Neurol; 2018 Oct; 75(10):1187-1197. PubMed ID: 29987329
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines.
Robbins MS; Starling AJ; Pringsheim TM; Becker WJ; Schwedt TJ
Headache; 2016 Jul; 56(7):1093-106. PubMed ID: 27432623
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts.
Ruscheweyh R; Broessner G; Goßrau G; Heinze-Kuhn K; Jürgens TP; Kaltseis K; Kamm K; Peikert A; Raffaelli B; Rimmele F; Evers S
Cephalalgia; 2020 Dec; 40(14):1574-1584. PubMed ID: 32806953
[TBL] [Abstract][Full Text] [Related]
18. [Galcanezumab for episodic and chronic cluster headache].
Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
[TBL] [Abstract][Full Text] [Related]
19. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment.
Ashina H; Newman L; Ashina S
Neurol Sci; 2017 Dec; 38(12):2089-2093. PubMed ID: 28856479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
